The surface-first paradigm: Engineering nanocarriers for infection-responsive drug delivery.

The surface of a nanocarrier is the frontline interface between its therapeutic cargo and the complex biological milieu it encounters. While traditional drug delivery research has focused on payload optimisation, emerging challenges, such as antimicr…

Preview only. Read the full abstract at the source